secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-01-20T23:59:59+00:00
Accession:  0001193125-22-012763
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro
-----------------------------------------------------------------------------

- Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.
- Agreement effective through Dec 31, 2022; covers clinical and commercial supply for US and Canada.
- Aadi has minimum purchase obligations; failure triggers additional payment to Fresenius Kabi.
- Price fixed but subject to increase under specified circumstances; includes labeling/packaging services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/0001193125-22-012763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/d295801d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-012763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer